170 related articles for article (PubMed ID: 25314066)
1. Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study.
Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Shen CC; Ku FC; Chen SC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
Br J Cancer; 2015 Jan; 112(1):177-84. PubMed ID: 25314066
[TBL] [Abstract][Full Text] [Related]
2. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.
Atsuta Y; Suzuki R; Yamashita T; Fukuda T; Miyamura K; Taniguchi S; Iida H; Uchida T; Ikegame K; Takahashi S; Kato K; Kawa K; Nagamura-Inoue T; Morishima Y; Sakamaki H; Kodera Y;
Ann Oncol; 2014 Feb; 25(2):435-41. PubMed ID: 24399081
[TBL] [Abstract][Full Text] [Related]
3. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.
Chen MH; Chang PM; Li WY; Hsiao LT; Hong YC; Liu CY; Gau JP; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Bone Marrow Transplant; 2011 Apr; 46(4):567-72. PubMed ID: 20622906
[TBL] [Abstract][Full Text] [Related]
4. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy.
Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA;
Leukemia; 2015 Feb; 29(2):441-7. PubMed ID: 24962016
[TBL] [Abstract][Full Text] [Related]
5. Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation.
Torrent A; Ferrá C; Morgades M; Jiménez MJ; Sancho JM; Vives S; Batlle M; Moreno M; Xicoy B; Oriol A; Ibarra G; Ribera JM
Med Clin (Barc); 2018 Jun; 150(11):421-427. PubMed ID: 28874263
[TBL] [Abstract][Full Text] [Related]
6. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.
Cohen A; Rovelli A; Merlo DF; van Lint MT; Lanino E; Bresters D; Ceppi M; Bocchini V; Tichelli A; Socié G
J Clin Oncol; 2007 Jun; 25(17):2449-54. PubMed ID: 17557958
[TBL] [Abstract][Full Text] [Related]
7. Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.
Adhikari J; Sharma P; Bhatt VR
Future Oncol; 2015; 11(23):3175-85. PubMed ID: 26551415
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Center Experience.
Wang F; Cai B; Wang L; Gu Z; Luo L; Wei H; Zhao S; Guan L; Wang X; Wang L; Liu D; Gao C
Ann Transplant; 2017 Feb; 22():58-65. PubMed ID: 28154370
[TBL] [Abstract][Full Text] [Related]
9. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study.
Fan WC; Liu CJ; Hong YC; Feng JY; Su WJ; Chien SH; Chen TJ; Chiang CH
Int J Tuberc Lung Dis; 2015 Jan; 19(1):58-64. PubMed ID: 25519791
[TBL] [Abstract][Full Text] [Related]
10. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients.
Tichelli A; Beohou E; Labopin M; Socié G; Rovó A; Badoglio M; van Biezen A; Bader P; Duarte RF; Basak G; Salooja N;
JAMA Oncol; 2019 Feb; 5(2):229-235. PubMed ID: 30476975
[TBL] [Abstract][Full Text] [Related]
12. Health status, late effects and long-term survivorship of allogeneic bone marrow transplantation: a retrospective study.
Gifford G; Sim J; Horne A; Ma D
Intern Med J; 2014 Feb; 44(2):139-47. PubMed ID: 24320824
[TBL] [Abstract][Full Text] [Related]
13. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.
Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Tzeng CH
Br J Haematol; 2015 Jun; 169(5):737-45. PubMed ID: 25818840
[TBL] [Abstract][Full Text] [Related]
15. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
16. Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence.
Wang CH; Chang FY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2018 Feb; 51(1):123-131. PubMed ID: 27103500
[TBL] [Abstract][Full Text] [Related]
17. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study.
Chang KH; Hwang WL; Muo CH; Hsu CY; Teng CJ
Support Care Cancer; 2016 Dec; 24(12):4993-5000. PubMed ID: 27502072
[TBL] [Abstract][Full Text] [Related]
18. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.
Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159
[TBL] [Abstract][Full Text] [Related]
19. Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures.
Szlauer-Stefańska A; Kamińska-Winciorek G; Giebel S; Bagłaj M
Adv Clin Exp Med; 2020 Oct; 29(10):1221-1230. PubMed ID: 33064381
[TBL] [Abstract][Full Text] [Related]
20. The apheresis content analysis in Allo-HSCT represents reliable influential factors on graft-versus-host disease and overall survival.
Rauofi A; Hajifathali A; Karami S; Tavakoli F; Roshandel E; Bonakchi H; Parkhideh S
Transfus Apher Sci; 2021 Apr; 60(2):103009. PubMed ID: 33608218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
